Third Circuit Nixes Novo Nordisk Challenge to Medicare Drug Price Negotiation Program
- October 10, 2025
Drug maker Novo Nordisk failed October 6 to revive its challenge to the Medicare drug price negotiation program, with the Third Circuit rejecting the company’s statutory and constitutional claims.
ARTICLE TAGS
You must be logged in to access this content.